Recent advances in pathophysiological mechanisms of itch

Expert Review of Dermatology

Volumn 5, Issue 2, 2010, Pages 197-212

  Tominaga, Mitsutoshi ^a   Takamori, Kenji ^a,b  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

GRP GRPR; Histamine receptor; IL 31; NGF; Opioid system; Pruritogen; Sema3A; Sensory nerve fiber; Skin barrier

Indexed keywords

AMPHIREGULIN; CANNABINOID RECEPTOR; DESMOGLEIN 3; GAMMA INTERFERON; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; GELATINASE B; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 31; INTERLEUKIN 8; KAPPA OPIATE RECEPTOR; LEUKOTRIENE B4; MU OPIATE RECEPTOR; PROTEIN ZO1; PROTEIN ZO2; PROTEINASE ACTIVATED RECEPTOR 2; SEMAPHORIN 3A; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

CELL INTERACTION; CELL JUNCTION; CHOLESTASIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEFENSE MECHANISM; EPIDERMAL NERVE DENSITY; HISTAMINE RELEASE; HUMAN; INNATE IMMUNITY; KIDNEY FAILURE; NERVE ENDING; NERVE FIBER C; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECEPTOR BINDING; REVIEW; SCRATCHING; SEASONAL VARIATION; SKIN INFLAMMATION; SKIN RECEPTOR; SKIN TEMPERATURE; TEMPERATURE SENSITIVITY; TISSUE DISTRIBUTION;

EID: 77951627516     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.10.7     Document Type: Review

References (166)

1. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp. Dermatol. 11, 12-24 (2002).
2. Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F (Eds). Itch, Basic Mechanisms and Therapy. Marcel Dekker Inc, NY, USA (2004).
3. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat. Rev. Neurosci. 7, 535-547 (2006).
4. Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J. Clin. Invest. 116, 1174-1186 (2006).
5. Johnson HH Jr, Deoreo GA, Lascheid WP, Mitchell F. Skin histamine levels in chronic atopic dermatitis. J. Invest. Dermatol. 34, 237-238 (1960).
6. Juhlin L. Localization and content of histamine in normal and diseased skin. Acta Derm. Venereol. 47, 383-391 (1967).
7. Greaves MW, Sondergaard J. Urticaria pigmentosa and factitious urticaria. Direct evidence for release of histamine and other smooth muscle-contracting agents in dermographic skin. Arch. Dermatol. 101, 418-425 (1970).
8. Petersen LJ, Hansen U, Kristensen JK, Nielsen H, Skov PS, Nielsen HJ. Studies on mast cells and histamine release in psoriasis: the effect of ranitidine. Acta Derm. Venereol. 78, 190-193 (1998).
9. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br. J. Pharmacol. 142, 374-380 (2004).
10. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 119, 176-183 (2007).
11. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic infammation: the search for new antihistamines. Nat. Rev. Drug Discov. 7, 41-53 (2008).
12. Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, Werfel T The histamine H4 receptor is functionally expressed on T(H)2 cells. J. Allergy Clin. Immunol. 123, 619-625 (2009).
13. Sonkoly E, Muller A, Lauerma AI et al IL-31: a new link between T cells and pruritus in atopic skin infammation. J. Allergy Clin. Immunol. 117, 411-417 (2006).
14. Neis MM, Peters B, Dreuw A et al Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J. Allergy Clin. Immunol. 118, 930-937 (2006).
15. Raap U, Wichmann K, Bruder M et al Correlation of IL-31 serum levels with severity of atopic dermatitis. J. Allergy Clin. Immunol. 122, 421-423 (2008).
16. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur. J. Pharmacol. 516, 180-181 (2005).
17. Takaoka A, Arai I, Sugimoto M et al Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp. Dermatol. 15, 161-167 (2006).
18. Grimstad O, Sawanobori Y, Vestergaard C et al. Anti-interleukin-31- antibodies ameliorate scratching behavior in NC/Nga mice: a model of atopic dermatitis. Exp. Dermatol. 18, 35-43 (2009).
19. Arrang JM, Garbarg M, Lancelot JC et al Highly potent and selective ligands for histamine H3-receptors. Nature 327, 117-123 (1987).
20. Ichinose M, Barnes PJ. Inhibitory histamine H3-receptors on cholinergic nerves in human airways. Eur. J. Pharmacol. 163, 383-386 (1989).
21. Delaunois A, Gustin P, Garbarg M, Ansay M. Modulation of acetylcholine, capsaicin and substance P effects by histamine H3 receptors in isolated perfused rabbit lungs. Eur. J. Pharmacol. 277, 243-250 (1995).
22. Koss MC, Hey JA. Prejunctional inhibition of sympathetically evoked pupillary dilation in cats by activation of histamine H3 receptors. Arch. Pharmacol. 348, 141-145 (1993).
23. Ohkubo T, Shibata M, Inoue M, Kaya H, Takahashi H. Regulation of substance P release mediated via prejunctional histamine H3 receptors. Eur. J. Pharmacol 273, 83-88 (1995).
24. Sugimoto Y, Iba Y, Nakamura Y, Kayasuga R, Kamei C. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin. Exp. Allergy. 34, 456-459 (2004).
25. Temporin K, Tanaka H, Kuroda Y et al. IL-1b promotes neurite outgrowth by deactivating RhoA via p38 MAPK pathway. Biochem. Biophys. Res. Commun. 365, 375-380 (2008).
26. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA 258, 1624-1629 (1987).
27. Wahlgren CF, Tengvall Linder M, Hägermark O, Scheynius A. Itch and infammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch. Dermatol. Res. 287, 572-580 (1995).
28. Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-a) at the dermal-epidermal junction. Br. J. Dermatol. 137, 415-417 (1997).
29. van Joost T, Stolz E, Heule F. Effcacy of low-dose cyclosporin in severe atopic skin disease. Arch. Dermatol. 123, 166-167 (1987).
30. Wahlgren CF, Scheynius A, Hägermark O. Antipruritic effect of oral cyclosporine A in atopic dermatitis. Acta. Derm. Venereol. 70, 323-329 (1990).
31. Sticherling M, Bornscheuer E, Schröder JM, Christophers E. Immunohistochemical studies on NAP-1/IL-8 in contact eczema and atopic dermatitis. Arch. Dermatol. Res. 284, 82-85 (1992).
32. Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch. Dis. Child. 70, 119-122 (1994).
33. Yousef S, Hemmann S, Weber M et al. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J. Immunol. 154, 5481-5490 (1995).
34. Lippert U, Hoer A, Möller A, Ramboer I, Cremer B, Henz BM. Role of antigen-induced cytokine release in atopic pruritus. Int. Arch. Allergy Immunol. 116, 36-39 (1998).
35. Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage infammatory protein-1 a (MIP-1 a), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clin. Exp. Immunol. 117, 237-243 (1999).
36. Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 5, 752-760 (2004).
37. Heise R, Neis MM, Marquardt Y et al. IL-31 receptor a expression in epidermal keratinocytes is modulated by cell differentiation and interferon g. J. Invest Dermatol. 129, 240-243 (2009).
38. Kakurai M, Monteforte R, Suto H, Tsai M, Nakae S, Galli SJ. Mast cell-derived tumor necrosis factor can promote nerve fber elongation in the skin during contact hypersensitivity in mice. Am. J. Pathol. 169, 1713-1721 (2006).
39. Reinhold U, Kukel S, Brzoska J, Kreysel HW. Systemic interferon-g treatment in severe atopic dermatitis. J. Am. Acad. Dermatol. 29, 58-63 (1993).
40. Tanaka A, Jung K, Benyacoub J et al. Oral supplementation with Lactobacillus rhamnosus CGMCC 1.3724 prevents development of atopic dermatitis in NC/NgaTnd mice possibly by modulating local production of I FN-g. Exp. Dermatol. 18, 1022-1027 (2009).
41. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in infammation, neuronal signaling and pain. Trends Pharmacol. Sci. 22, 146-152 (2001).
42. Barry GD, Le GT, Fairlie DP. Agonists and antagonists of protease activated receptors (PARs). Curr. Med. Chem. 13, 243-265 (2006).
43. Steinhoff M, Vergnolle N, Young SH et al. Agonists of proteinase-activated receptor 2 induce infammation by a neurogenic mechanism. Nat. Med. 6, 151-158 (2000).
44. Steinhoff M, Neisius U, Ikoma A et al Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23, 6176-6180 (2003).
45. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol. Rev. 77, 1033-1079 (1997).
46. Molino M, Barnathan ES, Numerof R et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 272, 4043-4049 (1997).
47. Tsujii K, Andoh T, Ui H, Lee JB, Kuraishi Y Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J. Pharmacol. Sci. 109, 388-395 (2009).
48. Steinhoff M, Corvera CU, Thoma MS et al. Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp. Dermatol. 8, 282-294 (1999).
49. Andoh T, Katsube N, Maruyama M, Kuraishi Y Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J. Invest. Dermatol. 117, 1621-1626 (2001).
50. Andoh T, Kuraishi Y Nitric oxide enhances substance P-induced itch-associated responses in mice. Br. J. Pharmacol. 138, 202-208 (2003).
51. Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H, Narumiya S, Kuraishi Y Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J. Invest Dermatol. 127, 2042-2047 (2007).
52. Moormann C, Artuc M, Pohl E et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J. Invest. Dermatol. 126, 746-755 (2006).
53. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Bíró T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J. Invest. Dermatol. 126, 1705-1718 (2006).
54. Bíró T, Tóth BI, Marincsák R, Dobrosi N, Géczy T, Paus R. TRP channels as novel players in the pathogenesis and therapy of itch. Biochim. Biophys. Acta 1772, 1004-1021 (2007).
55. Tominaga M, Caterina MJ, Malmberg AB et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531-543 (1998).
56. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 24, 487-517 (2001).
57. Koplas PA, Rosenberg RL, Oxford GS. The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J. Neurosci. 17, 3525-3537 (1997).
58. Dai Y, Moriyama T, Higashi T et al. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced infammatory pain. J. Neurosci. 24, 4293-4299 (2004).
59. Kawao N, Shimada C, Itoh H, Kuroda R, Kawabata A. Capsazepine inhibits thermal hyperalgesia but not nociception triggered by pro tease-activated receptor-2 in rats. Jpn. J. Pharmacol. 89, 184-187 (2002).
60. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB. Activation of epidermal vanilloid receptor-1 induces release of proinfammatory mediators in human keratinocytes. J. Pharmacol. Exp. Ther. 304, 217-222 (2003).
61. Ständer S, Moormann C, Schumacher M et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fbers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 13, 129-139 (2004).
62. Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J. Am. Acad. Dermatol. 44, 471-478 (2001).
63. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 361, 690-694 (2003).
64. Peier AM, Reeve AJ, Andersson DA et al A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046-2049 (2002).
65. Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J. Biol. Chem. 279, 21569-21575 (2004).
66. Stokes AJ, Shimoda LM, Koblan-Huberson M, Adra CN, Turner H. A TRPV2-PKA signaling module for transduction of physical stimuli in mast cells. J. Exp. Med. 200, 137-147 (2004).
67. Moqrich A, Hwang SW, Earley TJ et al. Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307, 1468-1472 (2005).
68. Yoshioka T, Imura K, Asakawa M et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. J. Invest. Dermatol. 129, 714-722 (2009).
69. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424, 434-438 (2003).
70. Ständer S, Schneider SW, Weishaupt C, Luger TA, Misery L. Putative neuronal mechanisms of sensitive skin. Exp. Dermatol. 18, 417-423 (2009).
71. Story GM, Peier AM, Reeve AJ et al ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112, 819-829 (2003).
72. Bautista DM, Jordt SE, Nikai T et al. TRPA1 mediates the infammatory actions of environmental irritants and proalgesic agents. Cell 124, 1269-1282 (2006).
73. Atoyan R, Shander D, Botchkareva NV. Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J. Invest. Dermatol. 129, 2312-2315 (2009).
74. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. Br. J. Dermatol. 93, 303-312 (1975).
75. Serhan CN, Haeggström JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158 (1996).
76. Andoh T, Kuraishi Y Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur. J. Pharmacol. 353, 93-96 (1998).
77. Andoh T, Yageta Y, Takeshima H, Kuraishi Y Intradermal nociceptin elicits itch-associated responses through leukotriene B(4) in mice. J. Invest. Dermatol. 123, 196-201 (2004).
78. Greaves MW. Itch in systemic disease: therapeutic options. Dermatol. Ther. 18, 323-327 (2005).
79. Pisoni RL, Wikström B, Elder SJ et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 21, 3495-3505 (2006).
80. Narita I, Iguchi S, Omori K, Gejyo F. Uremic pruritus in chronic hemodialysis patients. J. Nephrol. 21, 161-165 (2008).
81. Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43, 1078-1088 (2005).
82. Tandon P, Rowe BH, Vandermeer B, Bain VG. The effcacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol 102, 1528-1536 (2007).
83. Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. Br. Med. J. 4, 693-695 (1974).
84. Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am. J. Gastroenterol. 82, 117-118 (1987).
85. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology. 11, 884-887 (1990).
86. Freedman MR, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role for bile acid retention. Am. J. Med. 70, 1011-1016 (1981).
87. Bartholomew TC, Summerfeld JA, Billing BH, Lawson AM, Setchell KD. Bile acid profles of human serum and skin interstitial fuid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin. Sci. (Lond). 63, 65-73 (1982).
88. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 31, 96-99 (1990).
89. Cousins MJ, Mather LE. Intrathecal and epidural administration of opioids. Anesthesiology 61, 276-310 (1984).
90. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 33, 149-160 (1988).
91. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin-where do we stand? Exp. Dermatol. 18, 424-430 (2009).
92. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel K-receptor agonist, nalfurafne hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol. Dial. Transplant. doi: 10.1093/ndt/gfp588 (2009) (Epub ahead of print).
93. Inan S, Cowan A. K opioid agonists suppress chloroquine-induced scratching in mice. Eur. J. Pharmacol. 502, 233-237 (2004).
94. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J. Invest. Dermatol. 127, 2228-2235 (2007).
95. Bigliardi PL, Stammer H, Jost G, Rufi T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J. Am. Acad. Dermatol 56, 979-988 (2007).
96. Roy S, Balasubramanian S, Sumandeep S et al. Morphine directs T cells toward T(H2) differentiation. Surgery 130, 304-309 (2001).
97. Sacerdote P, Gaspani L, Panerai AE. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann. NY Acad. Sci. 917, 755-763 (2000).
98. Stander S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of μ-opioid receptor 1A on sensory nerve fbers in human skin. Regul. Pept. 110, 75-83 (2002).
99. Bigliardi-Qi M, Lipp B, Sumanovski LT, Buechner SA, Bigliardi PL. Changes of epidermal μ-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 210, 91-99 (2005).
100. Rau KK, Caudle RM, Cooper BY, Johnson RD. Diverse immunocytochemical expression of opioid receptors in electrophysiologically defned cells of rat dorsal root ganglia. J. Chem. Neuroanat. 29, 255-264 (2005).
101. Tominaga M, Ogawa H, Takamori K. Histological characterization of cutaneous nerve fbers containing gastrin-releasing peptide in NC/Nga mice: an atopic dermatitis model. J. Invest. Dermatol. 129, 2901-2905 (2009)
102. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin-a possible target for future therapies in dermatology. Exp. Dermatol. 18, 669-679 (2009).
103. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613 (1988).
104. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
105. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
106. Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci. 65, 597-605 (1999).
107. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. 448, 410-422 (2002).
108. Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor-and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience 110, 747-753 (2002).
109. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fbers and adnexal structures in human skin. J. Dermatol. Sci. 38, 177-188 (2005).
110. Klein T W, Newton C, Larsen K et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496 (2003).
111. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not infammatory chronic pain models. Eur. J. Neurosci. 17, 2750-2754 (2003).
112. Maddison B, Namazi MR, Samuel LS et al. Unexpected diminished innervation of epidermis and dermoepidermal junction in lichen amyloidosus. Br. J. Dermatol. 159, 403-406 (2008).
113. Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br. J. Dermatol. 161, 1217-1224 (2009).
114. Bando T, Morikawa Y, Komori T, Senba E. Complete overlap of interleukin-31 receptor A and oncostatin M receptor b in the adult dorsal root ganglia with distinct developmental expression patterns. Neuroscience 142, 1263-1271 (2006).
115. Wallengren J, Tegner E, Sundler F. Cutaneous sensory nerve fbers are decreased in number after peripheral and central nerve damage. J. Am. Acad. Dermatol. 46, 215-217 (2002).
116. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci. 16, 353-359 (1993).
117. Verge VM, Richardson PM, Wiesenfeld-Hallin Z, Hokfelt T Differential infuence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J. Neurosci. 15, 2081-2096 (1995).
118. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T Modern aspects of cutaneous neurogenic infammation. Arch. Dermatol. 139, 1479-1488 (2003).
119. Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. J. Pharmacol. Sci. 99, 277-286 (2005).
120. Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of high-affnity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. Br. J. Dermatol. 156, 241-246 (2007).
121. Kimura H, Schubert D. Schwannoma-derived growth factor promotes the neuronal differentiation and survival of PC12 cells. J. Cell. Biol. 116, 777-783 (1992).
122. Nilsson A, Kanje M. Amphiregulin acts as an autocrine survival factor for adult sensory neurons. Neuroreport 16, 213-218 (2005).
123. Tominaga M, Ozawa S, Ogawa H, Takamori K. A hypothetical mechanism of intraepidermal neurite formation in NC/Nga mice with atopic dermatitis. J. Dermatol. Sci. 46, 199-210 (2007).
124. Kansra S, Stoll SW, Johnson JL, Elder JT Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol. Biol. Cell 15, 4299-4309 (2004).
125. Shubayev VI, Myers RR. Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J. Neurosci. Res. 77, 229-239 (2004).
126. Gschwandtner M, Purwar R, Wittmann M et al. Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J. Invest. Dermatol. 128, 2783-2791 (2008).
127. Purwar R, Kraus M, Werfel T, Wittmann M. Modulation of keratinocyte-derived MMP-9 by IL-13: a possible role for the pathogenesis of epidermal infammation. J. Invest. Dermatol. 128, 59-66 (2008).
128. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Increased plasma tumour necrosis factor-a concentration in atopic dermatitis. Arch. Dis. Child. 67, 277-279 (1992).
129. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumour necrosis factor-a (TNF-a) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin. Exp. Immunol. 94, 354-362 (1993).
130. Shubayev VI, Myers RR. Axonal transport of TNF-a in painful neuropathy: distribution of ligand tracer and TNF receptors. J. Neuroimmunol. 114, 48-56 (2004).
131. Takaoka K, Shirai Y, Saito N. Infammatory cytokine tumor necrosis factor-a enhances nerve growth factor production in human keratinocytes, HaCaT cells. J. Pharmacol Sci. 11, 381-391 (2009).
132. Fujisawa H. Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J. Neurobiol. 59, 24-33 (2004).
133. Messersmith EK, Leonardo ED, Shatz CJ, Tessier-Lavigne M, Goodman CS, Kolodkin AL. Semaphorin III can function as a selective chemorepellent to pattern sensory projections in the spinal cord. Neuron 14, 949-959 (1995).
134. Shepherd IT, Luo Y, Lefcort F, Reichardt LF, Raper JA. A sensory axon repellent secreted from ventral spinal cord explants is neutralized by antibodies raised against collapsin-1. Development 124, 1377-1385 (1997).
135. Dontchev VD, Letourneau PC. Nerve growth factor and semaphorin 3A signaling pathways interact in regulating sensory neuronal growth cone motility. J. Neurosci. 22, 6659-6669 (2002).
136. Tominaga M, Ogawa H, Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br. J. Dermatol. 158, 842-844 (2008).
137. Tang XQ, Tanelian DL, Smith GM. Semaphorin3A inhibits nerve growth factor-induced sprouting of nociceptive afferents in adult rat spinal cord. J. Neurosci. 24, 819-827 (2004).
138. Yamaguchi J, Nakamura F, Aihara M et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J. Invest. Dermatol. 128, 2842-2849 (2008).
139. Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J. Dermatol. Sci. 55, 40-46 (2009).
140. Loden M, Maibach HI. Dry Skin and Moisturizers: Chemistry and Function. Taylor & Francis Group, FL, USA (2006).
141. Yosipovitch G. Dry skin and impairment of barrier function associated with itch-new insights. Int. J. Cosmet. Sci. 26, 1-7 (2004).
142. Pinnagoda J, Tupker RA, Coenraads PJ, Nater JP. Prediction of susceptibility to an irritant response by transepidermal water loss. Contact Dermatitis 20, 341-346 (1989). (Pubitemid 19167186)
143. Rycroft RJG, Smith WDL. Low humidity occupational dermatoses. Contact Dermatitis 6, 488-492 (1980).
144. Chernosky ME. Clinical aspects of dry skin. J. Soc. Cosmet. Chem. 27, 365-376 (1976).
145. Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. J. Invest. Dermatol. 103, 731-741 (1994).
146. Tominaga M, Ozawa S, Tengara S, Ogawa H, Takamori K. Intraepidermal nerve fbers increase in dry skin of acetone-treated mice. J. Dermatol. Sci. 48, 103-111 (2007).
147. Grubauer G, Elias PM, Feingold KR. Transepidermal water loss: the signal for recovery of barrier structure and function. J. Lipid Res. 30, 323-333 (1989).
148. Miyamoto T, Nojima H, Shinkado T, Nakahashi T, Kuraishi Y Itch-associated response induced by experimental dry skin in mice. Jpn. J. Pharmacol. 88, 285-292 (2002). (Pubitemid 34302979)
149. Tominaga M, Takamori K. The penetration mechanisms of nerve fbers into the epidermis of atopic dermatitis. J. Environ. Dermatol. Cutan. Allergol. 3, 70-77 (2009).
150. Liou A, Elias PM, Grunfeld C, Feingold KR, Wood LC. Amphiregulin and nerve growth factor expression are regulated by barrier status in murine epidermis. J. Invest. Dermatol. 108, 73-77 (1997).
151. Yamaoka J, Di ZH, Sun W, Kawana S. Changes in cutaneous sensory nerve fbers induced by skin-scratching in mice. J. Dermatol. Sci. 46, 41-51 (2007).
152. Pummi K, Malminen M, Aho H, Karvonen SL, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes. J. Invest. Dermatol. 117, 1050-1058 (2001).
153. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 112, 535-548 (2003).
154. Zhou S, Matsuyoshi N, Takeuchi T, Ohtsuki Y, Miyachi Y Reciprocal altered expression of T-cadherin and P-cadherin in psoriasis vulgaris. Br. J. Dermatol. 149, 268-273 (2003).
155. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 36, 1206-1237 (2004).
156. Cook PW, Piepkorn M, Clegg CH et al Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 100, 2286-2294 (1997).
157. Cook PW, Brown JR, Cornell KA, Pittelkow MR. Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp. Dermatol. 13, 347-356 (2004).
158. Chung E, Cook PW, Parkos CA, Park YK, Pittelkow MR, Coffey RJ. Amphiregulin causes functional down regulation of adherens junctions in psoriasis. J. Invest. Dermatol. 124, 1134-1140 (2005).
159. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu. Rev. Cell. Dev. Biol. 19, 207-235 (2003).
160. Merritt AJ, Berika MY, Zhai W et al Suprabasal desmoglein 3 expression in the epidermis of transgenic mice results in hyperproliferation and abnormal differentiation. Mol. Cell. Biol. 22, 5846-5858 (2002).
161. Wittmann M, Werfel T. Interaction of keratinocytes with infltrating lymphocytes in allergic eczematous skin diseases. Curr. Opin. Allergy Clin. Immunol. 6, 329-334 (2006).
162. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specifc C-receptors for itch in human skin. J. Neurosci. 17, 8003-8008 (1997).
163. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 4, 72-77 (2001).
164. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensatio in the spinal cord. Nature 448, 700-703 (2007).
165. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science 325, 1531-1544 (2009)
166. Nakano T, Andoh T, Lee JB, Kuraishi Y Different dorsal horn neurons responding to histamine and allergic itch stimuli. Neuroreport 19, 723-726 (2008).